{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:35:38Z","timestamp":1791498938297,"version":"4.3.4"},"reference-count":91,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Mattioli 1885","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100015756","name":"Cilag","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>MCL is an uncommon lymphoproliferative disorder that has been regarded as incurable since its identification as a distinct entity. Allogeneic transplantation for two decades has represented the only option capable of ensuring prolonged remissions and possibly cure. Despite its efficacy, its application has been limited by feasibility limitations and substantial toxicity, particularly in elderly patients. Nevertheless, the experience accumulated over time has been wide though often scattered among retrospective and small prospective studies. In this review, we aimed at critically revise and discuss available evidence on allogeneic transplantation in MCL, trying to put available evidence into the 2020 perspective, characterized by unprecedented development of novel promising therapeutic agents and regimens.<\/jats:p>","DOI":"10.3390\/cancers13020291","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T11:39:14Z","timestamp":1610624354000},"page":"291","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy"],"prefix":"10.3390","volume":"13","author":[{"given":"Miriam","family":"Marangon","sequence":"first","affiliation":[{"name":"Department of Hematology, Azienda Sanitaria Universitaria Giuliano Isontina, 34129 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2863-0883","authenticated-orcid":false,"given":"Carlo","family":"Visco","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medicine, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Barbui","sequence":"additional","affiliation":[{"name":"Hematology Unit, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Chiappella","sequence":"additional","affiliation":[{"name":"Division of Hematology, Fondazione IRCCS, Istituto Nazionale dei Tumori, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Fabbri","sequence":"additional","affiliation":[{"name":"Hematology Division, Department of Oncology, Azienda Ospedaliero-Universitaria Senese, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9711-1502","authenticated-orcid":false,"given":"Simone","family":"Ferrero","sequence":"additional","affiliation":[{"name":"Hematology Division, Department of Molecular Biotechnologies and Health Sciences, Universit\u00e0 di Torino, 10126 Torino, Italy"},{"name":"Hematology 1, AOU Citt\u00e0 della Salute e della Scienza di Torino, 10126 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7899-5966","authenticated-orcid":false,"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-2285","authenticated-orcid":false,"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Unit\u00e0 Sanitaria Locale IRCCS di Reggio Emilia, 42123 Modena, Italy"},{"name":"Surgical, Medical and Dental Department of Morphological Sciences Related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, 42123 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Musuraca","sequence":"additional","affiliation":[{"name":"Department of Hematology, IRCCS\u2014Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1156-6395","authenticated-orcid":false,"given":"Alessandro","family":"Re","sequence":"additional","affiliation":[{"name":"Hematology Unit, ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6915-2246","authenticated-orcid":false,"given":"Vittorio Ruggero","family":"Zilioli","sequence":"additional","affiliation":[{"name":"Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ladetto","sequence":"additional","affiliation":[{"name":"SC Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy"},{"name":"Dipartimento di Medicina Traslazionale, Universit\u00e0 del Piemonte Orientale, 15121 Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.14694\/EdBook_AM.2014.34.191","article-title":"European Mantle Cell Lymphoma Network Mantle cell lymphoma: Biology, clinical presentation, and therapeutic approaches","volume":"34","author":"Dreyling","year":"2014","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/bjh.12854","article-title":"SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma\u2014A Nordic Lymphoma Group study","volume":"166","author":"Sernbo","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: Results from randomized trials of the european mantle cell lymphoma network","volume":"34","author":"Hoster","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): A randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma N","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma","volume":"377","author":"Thieblemont","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S2352-3026(20)30358-6","article-title":"Lenalidomide maintenance after autologous stem cell transplantation in mantle cell lymphoma (MCL): Results of a \u201cFondazione Italiana Linfomi\u201d (FIL) multicentre randomised phase III trial","volume":"8","author":"Ladetto","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.13796","article-title":"Rituximab plus hyper-CVAD alternating with MTX\/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center","volume":"172","author":"Chihara","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Massaro, F., Stepanishyna, Y., Manni, M., Luminari, S., Galimberti, S., Marcheselli, L., Visco, C., Tecchio, C., Stelitano, C., and Angrilli, F. (2020). Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma. Br. J. Haematol.","DOI":"10.1111\/bjh.16714"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with Mantle-Cell Lymphoma","volume":"367","author":"Hoster","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","article-title":"Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: A multicentre, randomised, open-label, non-inferiority phase 3 trial","volume":"17","author":"Rummel","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: Results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(16)30185-5","article-title":"Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: A multicentre, phase 2 trial from Fondazione Italiana Linfomi","volume":"4","author":"Visco","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00277-014-2049-5","article-title":"Mantle cell lymphoma epidemiology: A population-based study in France","volume":"93","author":"Leux","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/10428194.2018.1468894","article-title":"Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: Results from a single institution study","volume":"60","author":"Faramand","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41409-017-0067-3","article-title":"Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: A retrospective study from the EBMT Lymphoma Working Party","volume":"53","author":"Robinson","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.29498","article-title":"Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"121","author":"Vaughn","year":"2015","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/annonc\/mds054","article-title":"Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed\/refractory mantle cell lymphoma: A multicenter experience","volume":"23","author":"Dhedin","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.bbmt.2010.04.006","article-title":"Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): A study of the British society for blood and marrow transplantation","volume":"16","author":"Cook","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12185-019-02784-x","article-title":"JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-4. Mantle cell lymphoma (MCL)","volume":"111","author":"Okamoto","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bjh.15283","article-title":"Guideline for the management of mantle cell lymphoma","volume":"182","author":"McKay","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Carreras, E., Dufour, C., Mohty, M., and Kr\u00f6ger, N. (2019). Mantle Cell Lymphoma. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies, Springer Open.","DOI":"10.1007\/978-3-030-02278-5"},{"key":"ref_25","unstructured":"National Comprehensive Cancer Network (2020, October 22). Comprehensive Cancer Network Guideline\u2014B Cell Lymphomas. Available online: www.nccn.org."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1080\/10428194.2017.1403602","article-title":"Treatment for patients with relapsed\/refractory mantle cell lymphoma: European-based recommendations","volume":"59","author":"Dreyling","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/bjh.15643","article-title":"Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death","volume":"185","author":"Visco","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Visco, C., Di Rocco, A., Evangelista, A., Quaglia, F.M., Tisi, M.C., Morello, L., Zilioli, V.R., Rusconi, C., Hohaus, S., and Sciarra, R. (2020). Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: Results from the MANTLE-FIRST study. Leukemia.","DOI":"10.1038\/s41375-020-01013-3"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/annonc\/mdu097","article-title":"Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: A retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"25","author":"Dietrich","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00277-014-2087-z","article-title":"Allogeneic stem cell transplantation for mantle cell lymphoma-final report from the prospective trials of the East German Study Group Haematology\/Oncology (OSHO)","volume":"93","author":"Hirt","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2014.223","article-title":"The EBMT\/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma","volume":"29","author":"Robinson","year":"2015","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjh.15723","article-title":"Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma","volume":"184","author":"Rule","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","article-title":"Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: Analysis of transplantation timing and modality","volume":"32","author":"Fenske","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/bmt.2016.102","article-title":"Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: A national survey of the SFGM-TC","volume":"51","author":"Tessoulin","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/ejh.12442","article-title":"Role of allogeneic stem cell transplantation in mantle cell lymphoma","volume":"94","author":"Cohen","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1182\/blood-2014-06-584193","article-title":"miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator","volume":"125","author":"Husby","year":"2015","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/bjh.15518","article-title":"The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy","volume":"183","author":"Holte","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3324\/haematol.2017.184325","article-title":"A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: Results from the Fondazione Italiana Linfomi MCL-0208 trial","volume":"103","author":"Bomben","year":"2018","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/gcc.22849","article-title":"Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A\/B loss, and TP53 mutations: A multi-institutional study","volume":"59","author":"Streich","year":"2020","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.anndiagpath.2019.05.004","article-title":"TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant","volume":"41","author":"Sakhdari","year":"2019","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network","volume":"131","author":"Aukema","year":"2018","journal-title":"Blood"},{"key":"ref_42","first-page":"EP1160","article-title":"Focus on Patients with TP53 Disruption in the Fondazione Italiana Linfomi (FIL) MCL0208 Trial: Uniform Poor Outcome, Regardless of Baseline Predictors, MRD Status and Lenalidomide Maintenance","volume":"293649","author":"Ferrero","year":"2020","journal-title":"EHA Library"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: A FIL study","volume":"105","author":"Ferrero","year":"2020","journal-title":"Haematologica"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bjh.15721","article-title":"Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations","volume":"184","author":"Lin","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.clml.2013.10.007","article-title":"Hematopoietic cell transplantation for mantle cell lymphoma: Predictive value of pretransplant positron emission tomography\/computed tomography and bone marrow evaluations for outcomes","volume":"14","author":"Magnusson","year":"2014","journal-title":"Clin. Lymphoma. Myeloma Leuk."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009","article-title":"Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41409-018-0207-4","article-title":"Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: A study by the EBMT Chronic Malignancies and Lymphoma Working Parties","volume":"54","author":"Dreger","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.bbmt.2015.05.007","article-title":"Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma","volume":"21","author":"Bachanova","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","article-title":"Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study","volume":"32","author":"Rule","year":"2018","journal-title":"Leukemia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","article-title":"Treatment of patients with relapsed or refractory Mantle-Cell Lymphoma with zanubrutinib, a selective inhibitor of Bruton\u2019s Tyrosine Kinase","volume":"26","author":"Song","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood.2019852368","article-title":"Acalabrutinib for mantle cell lymphoma","volume":"133","author":"Witzig","year":"2019","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","author":"Eyre","year":"2019","journal-title":"Haematologica"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus Venetoclax for the treatment of Mantle-Cell Lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16416","article-title":"Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy","volume":"189","author":"McCulloch","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1200\/JCO.2010.32.8419","article-title":"Allogeneic Transplantation for Lymphoma","volume":"29","author":"Chakraverty","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/PPO.0b013e31826b124c","article-title":"Non-myeloablative allogeneic stem cell transplantation for non-Hodgkin lymphoma","volume":"18","author":"Khouri","year":"2012","journal-title":"Cancer J."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Appelbaum, F.R. (2008). Allogeneic hematopoietic cell transplantation for acute myeloid leukemia when a matched related donor is not available. Hematol. Am. Soc. Hematol. Educ. Progr., 412\u2013417.","DOI":"10.1182\/asheducation-2008.1.412"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood-2013-02-453175","article-title":"Umbilical cord blood transplantation: The first 25 years and beyond","volume":"122","author":"Ballen","year":"2013","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs. HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2005-05-2146","article-title":"Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched\/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation","volume":"107","author":"Lu","year":"2006","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/cncr.27761","article-title":"Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: Nine years of experience at a single center","volume":"119","author":"Wang","year":"2013","journal-title":"Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: A center for international blood and marrow transplant research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjh.16182","article-title":"Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma\u2014a LWP-EBMT study","volume":"188","author":"Bazarbachi","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.19.02408","article-title":"Nonmyeloablative alternative donor transplantation for Hodgkin and non-Hodgkin lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR","volume":"38","author":"Fatobene","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood.V77.3.649.649","article-title":"Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation","volume":"77","author":"Jones","year":"1991","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood.V84.4.1050.1050","article-title":"Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin\u2019s lymphoma","volume":"84","author":"Ratanatharathorn","year":"1994","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/sj.bmt.1702625","article-title":"Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin\u2019s lymphoma (NHL): Results of a provincial strategy","volume":"26","author":"Schimmer","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"Loberiza","year":"2003","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2003.08.054","article-title":"Syngeneic Hematopoietic Stem-Cell Transplantation for Non-Hodgkin\u2019s Lymphoma: A Comparison With Allogeneic and Autologous Transplantation\u2014The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood","volume":"21","author":"Bierman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.bmt.1700781","article-title":"Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect","volume":"19","author":"Giralt","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/sj.bmt.1704290","article-title":"Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation","volume":"32","author":"Mandigers","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/j.seminoncol.2003.10.017","article-title":"Nonmyeloablative stem cell transplantation for lymphoma","volume":"31","author":"Khouri","year":"2004","journal-title":"Semin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1705008","article-title":"The graft-versus-lymphoma effect: Clinical review and future opportunities","volume":"36","author":"Butcher","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3109\/10428190903275594","article-title":"Pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell lymphoma after allogeneic stem cell transplantation","volume":"51","author":"Cavattoni","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-Emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00277-013-1797-y","article-title":"Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma","volume":"92","author":"Ferrero","year":"2013","journal-title":"Ann. Hematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/bmt.2015.12","article-title":"Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party","volume":"50","author":"Horstmann","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.bbmt.2011.02.009","article-title":"Relapse of lymphoma after allogeneic hematopoietic cell transplantation: Management strategies and outcome","volume":"17","author":"Wudhikarn","year":"2011","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/ccr3.2257","article-title":"Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review","volume":"7","author":"Rich","year":"2019","journal-title":"Clin. Case Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1182\/blood.V126.23.4345.4345","article-title":"Ibrutinib in Patients (Pts) with Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) with Relapsed Disease Post Allogeneic Stem Cell Transplantation (alloSCT)","volume":"126","author":"Khouri","year":"2015","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1182\/blood.V128.22.4659.4659","article-title":"Salvage use of ibrutinib after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for B cell malignancies: A study of the French Cooperative Group for CLL, the French Soceity for Blood and Marrow Transplantation (SFGM-TC), and the European Soc","volume":"128","author":"Michallet","year":"2016","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41409-019-0742-7","article-title":"Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia","volume":"55","author":"Michallet","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41409-020-0982-6","article-title":"Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells","volume":"56","author":"Gu","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-020-00873-7","article-title":"Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed\/refractory acute lymphoblastic leukemia: A multi-center retrospective study","volume":"13","author":"Zhao","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.3389\/fimmu.2020.611710","article-title":"How to Combine the Two Landmark Treatment Methods\u2014Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/bmj.2.4993.626","article-title":"Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication","volume":"2","author":"Barnes","year":"1956","journal-title":"Br. Med. J."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/2\/291\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:11:10Z","timestamp":1760159470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/2\/291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":91,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["cancers13020291"],"URL":"https:\/\/doi.org\/10.3390\/cancers13020291","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,14]]}}}